<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511459</url>
  </required_header>
  <id_info>
    <org_study_id>20060341</org_study_id>
    <nct_id>NCT00511459</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients</brief_title>
  <official_title>A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, randomized, placebo controlled, multi-center study to estimate the&#xD;
      treatment effect and evaluate the safety and tolerability of AMG 386 in combination with&#xD;
      paclitaxel and paclitaxel/bevacizumab in the treatment of subjects with Her2-negative&#xD;
      metastatic or locally recurrent breast cancer.&#xD;
&#xD;
      AMG 386 is a man-made medication that is designed to stop the development of blood vessels in&#xD;
      cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called&#xD;
      angiogenesis, to obtain a supply of oxygen and nutrients to grow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To estimate the treatment effect as measured by progression free survival&#xD;
      (PFS) of subjects receiving AMG 386 (at 2 doses) in combination with paclitaxel + bevacizumab&#xD;
      relative to paclitaxel + bevacizumab + placebo.&#xD;
&#xD;
      Secondary Objective(s):&#xD;
&#xD;
        -  To compare the treatment effect as measured by PFS of subjects receiving open-label AMG&#xD;
           386 in combination with paclitaxel relative to paclitaxel + bevacizumab + placebo&#xD;
&#xD;
        -  To compare the treatment effect as measured by PFS of subjects receiving AMG 386 in&#xD;
           combination with paclitaxel and bevacizumab relative to paclitaxel + AMG 386&#xD;
&#xD;
        -  To evaluate the safety and tolerability of the combination and non-bevacizumab regimens&#xD;
&#xD;
        -  To estimate other measures (RR, DOR, TTR, TTP) of treatment effect&#xD;
&#xD;
        -  To evaluate the pharmacokinetics (PK) of AMG 386 and bevacizumab when used in&#xD;
           combination&#xD;
&#xD;
        -  To estimate the incidence of anti-AMG386 antibody formation&#xD;
&#xD;
      Exploratory Objective(s):&#xD;
&#xD;
        -  To explore the pharmacodynamic (PD) response as assessed by changes in blood levels of&#xD;
           angiogenic cytokines, tumor apoptosis, and other markers&#xD;
&#xD;
        -  To explore the association of histological features and selected immunologic,&#xD;
           biochemical, pharmacogenetic, or angiogenic markers in tumor biopsies, plasma, or serum&#xD;
           samples with safety and/or efficacy outcomes&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This is a phase 2, randomized, placebo controlled, multi-center study to estimate the&#xD;
      treatment effect and evaluate the safety and tolerability of AMG 386 in combination with&#xD;
      paclitaxel and paclitaxel/bevacizumab in the treatment of subjects with Her2-negative&#xD;
      metastatic or locally recurrent breast cancer.&#xD;
&#xD;
      Two hundred twenty subjects will be randomized 1:1:1:1 to each of the following arms:&#xD;
&#xD;
      Arm A: Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10&#xD;
      mg/kg IV QW Arm B: Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG&#xD;
      386 3 mg/kg IV QW Arm C: Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W&#xD;
      + AMG 386 placebo IV QW Arm D: Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10&#xD;
      mg/kg IV QW To maintain the double-blind in arms A, B, and C, each subject will be infused&#xD;
      weekly with a volume of investigational product equivalent to 10 mg/kg AMG 386 IV. Arm D will&#xD;
      receive open label AMG 386 and will not receive a placebo for bevacizumab.&#xD;
&#xD;
      Subjects will be discontinued from study treatment at any time for radiographic disease&#xD;
      progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or&#xD;
      death.&#xD;
&#xD;
      Subjects alive at the time of discontinuation of all study medications will be followed for&#xD;
      up to 48 months from the date of the last subject enrolled into the trial to evaluate overall&#xD;
      survival.&#xD;
&#xD;
      Radiological imaging to assess disease status will be performed every 8 weeks ± 7 days (2&#xD;
      cycles) for 2 years and then every 4 months ± 1 month thereafter during the study until&#xD;
      subjects develop radiographic disease progression per the modified RECIST criteria. In&#xD;
      addition, any subject who discontinues study drug treatment prior to disease progression will&#xD;
      continue to have radiological imaging performed every 8 weeks ± 7 days during the long term&#xD;
      follow up period if the subject has not been in the study for 2 years until the subject&#xD;
      develops radiographic disease progression or begins a new treatment. If the subject has been&#xD;
      on study for 2 years, radiological imaging every 4 months ± 1 month will be performed during&#xD;
      long term follow-up period until the subject develops radiographic disease progression or&#xD;
      begins a new treatment.&#xD;
&#xD;
      The overall study design is described by a study schema immediately following this synopsis.&#xD;
      Amgen Global Safety (AGS) will charter a data review team (DRT) that is independent of the&#xD;
      team conducting the study and will review unblinded safety data after 20, 40, and 80 subjects&#xD;
      have been randomized and have had the opportunity to receive at least 1 cycle (4 weeks) of&#xD;
      study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3 YEARS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR)</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs and significant laboratory changes</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMG 386 Pharmakokinetic parameters</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the occurrence of anti-AMG 386 antibody formation</measure>
    <time_frame>3 YEARS</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Locally Recurrent and Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 Placebo</intervention_name>
    <description>AMG 386 Placebo [blinded]</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386</intervention_name>
    <description>AMG 386 3mg/kg IV QW [blinded]</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 10mg/kg IV Q2W</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386</intervention_name>
    <description>AMG 386 10mg/kg IV QW [Open-Label]</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386</intervention_name>
    <description>AMG 386 10mg/kg IV QW [blinded]</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have histologically or cytologically confirmed adenocarcinoma of the&#xD;
             breast with locally recurrent or metastatic disease. Locally recurrent disease must&#xD;
             not be amenable to resection with curative intent.&#xD;
&#xD;
          -  Measurable or non-measurable disease per modified RECIST guidelines&#xD;
&#xD;
          -  ECOG of 0 or 1 (within 14 days prior to randomization)&#xD;
&#xD;
          -  Adequate organ and hematological function as evidenced by the following laboratory&#xD;
             studies within 14 days prior to randomization:&#xD;
&#xD;
             • Cardiac function, as follows:&#xD;
&#xD;
          -  Normal sinus rhythm (no significant ECG changes)&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ LLN, as determined by echocardiogram or MUGA&#xD;
             scan, according to institutional standards within 28 days prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory Breast Cancer&#xD;
&#xD;
          -  Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 peripheral&#xD;
             neuropathy &gt; grade 1 at randomization&#xD;
&#xD;
          -  History of arterial or venous thrombosis, including transient ischemic attack (TIA),&#xD;
             within 1 year prior to randomization&#xD;
&#xD;
          -  Adjuvant or neoadjuvant taxane treatment within 12 months of randomization. Any other&#xD;
             adjuvant chemotherapy regimen must be discontinued at least 21 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Prior chemotherapy, vaccine, or biological therapy for locally recurrent or metastatic&#xD;
             breast cancer (prior endocrine therapy is permitted)&#xD;
&#xD;
          -  Prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic&#xD;
             chemoembolization on all sites of disease unless disease progression was subsequently&#xD;
             documented 14 days prior to randomization.&#xD;
&#xD;
          -  Overexpression of HER-2 (gene amplification by FISH or 3+ over expression by&#xD;
             immunohistochemistry).&#xD;
&#xD;
          -  Current or prior history of central nervous system metastasis&#xD;
&#xD;
          -  History of bleeding diathesis or clinically significant bleeding within 6 months prior&#xD;
             to randomization&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to randomization&#xD;
&#xD;
          -  Open breast biopsy within 14 days prior to randomization&#xD;
&#xD;
          -  Minor surgical procedure, placement of access device, or fine needle aspiration within&#xD;
             7 days of first dose&#xD;
&#xD;
          -  Prior malignancy (other than thyroid cancer, in situ cervical cancer, or basal cell&#xD;
             cancer of the skin, treated with curative intent and without evidence of disease for ≥&#xD;
             3 years prior to randomization)&#xD;
&#xD;
          -  Clinically significant cardiac disease within 12 months prior to randomization,&#xD;
             including myocardial infarction, unstable angina, grade 2 or greater peripheral&#xD;
             vascular disease, cerebrovascular accident, transient ischemic attack, congestive&#xD;
             heart failure, or arrhythmias not controlled by outpatient medication&#xD;
&#xD;
          -  Non-healing wound, ulcer or fracture&#xD;
&#xD;
          -  Known hypersensitivity to paclitaxel or drugs using the vehicle cremophor&#xD;
&#xD;
          -  Known hypersensitivity to bacterial proteins, or any of the drugs required in this&#xD;
             study&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis&#xD;
             B surface antigen&#xD;
&#xD;
          -  Known active or chronic hepatitis&#xD;
&#xD;
          -  Uncontrolled hypertension as defined as systolic blood pressure ≥ 150 mm Hg and&#xD;
             diastolic blood pressure ≥ 90 mm Hg. Anti-hypertensive medications are allowed if the&#xD;
             subject is stable on their current dose at the time of randomization&#xD;
&#xD;
          -  Currently or previously treated with any VEGF or VEGFr inhibitor, including but not&#xD;
             limited to, bevacizumab, SU11248 (sunitinib), PTK787 (vatalinib), AZD 2171, AEE-788,&#xD;
             BAY 43-9006 (sorafenib) and AMG 706.&#xD;
&#xD;
          -  Treatment with coumarin-type anticoagulants, (other than low dose prophylaxis for&#xD;
             central venous catheters ≤ 1mg/day) within 7 days prior to randomization&#xD;
&#xD;
          -  Currently or previously treated with angiopoietin inhibitors, or inhibitors of TIE-1&#xD;
             or TIE-2 including, but not limited to, AMG 386, XL880, XL820&#xD;
&#xD;
          -  Treatment with immune modulators such as cyclosporine and tacrolimus within 30 days&#xD;
             prior to randomization&#xD;
&#xD;
          -  Concomitant therapy with any hormonal agent such as raloxifene, tamoxifen, or other&#xD;
             selective estrogen receptor modulators (SERMS), given for breast cancer prevention or&#xD;
             for osteoporosis. Subjects must have discontinued these agents 28 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Pregnant (ie, positive beta-human chorionic gonadotropin test) or is breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <zip>85340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mountain Lakes</city>
        <state>New Jersey</state>
        <zip>07046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Roche Sur Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 5</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miraj</city>
        <state>Maharashtra</state>
        <zip>416 410</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubin</city>
        <zip>59-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>JaÃ©n</city>
        <state>AndalucÃ-a</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sabadell</city>
        <state>CataluÃ±a</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <disposition_first_submitted>March 27, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 23, 2014</disposition_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>4-Arm</keyword>
  <keyword>Placebo controlled</keyword>
  <keyword>Phase 2 Trial</keyword>
  <keyword>AMG 386</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>First-line Therapy</keyword>
  <keyword>Her-2 Negative</keyword>
  <keyword>Metastatic or Locally Recurrent Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Trebananib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

